Validation and incidence of community-acquired pneumonia in patients with type 2 diabetes in the BIFAP database | Epidemiology & Infection | Cambridge Core Validation and incidence of community-acquired pneumonia in patients with type 2 diabetes in the BIFAP database - Volume 145 Issue 14

Validación e incidencia de neumonía adquirida en la comunidad en pac con DM2 en la base de datos #BIFAP [Epid & Inf] https://t.co/xVHrpOYEkR

Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis - Archives of Osteoporosis Summary Among 95,057 patients ≥50 years with new anti-osteoporosis medications (AOM) (2001–2013) in primary care, 1-year cessation was 51% (28%–68%), higher in men, smokers, patients with missing lifestyle data, and out normal BMI, and lower in those aged 60–79, with recent fractures or other anti-osteoporotics, suggesting non-severe osteoporosis and less risk awareness. Purpose Low compliance to anti-osteoporosis medications (AOM) has been previously reported. We aimed to estimate 1-year cessation rates of different AOMs as used in Spanish healthcare settings, and to identify associated risk factors. Methods A cohort study was performed using primary care records data (BIFAP). Patients entered the cohort when aged 50 years in 2001–2013, with ≥1 year of data available, and identified as incident users of AOM (1-year washout). Participants were divided into six cohorts: alendronate, other oral bisphosphonates, selective oestrogen receptor modulators, strontium ranelate, teriparatide, and denosumab. Patients were followed from therapy initiation to the earliest of cessation (90-day refill gap), switching (to alternative AOM), loss to follow-up, death, or end of 2013. One-year therapy cessation was estimated using life tables. Hazard ratios (of cessation) according to age, sex, lifestyle factors, morbidity, and co-medication were estimated after stepwise backwards selection. Results A total of 95,057 AOM users were identified (91% women; mean age 68). One-year cessation was 51% overall, highest for strontium ranelate (68%), and lowest for denosumab (28%). Cessation probability was higher in men (14% to 2.1-fold), smokers (>6%), and patients with missing BMI (19–28%) or smoking (6–20%) data, and overweight/obese/underweight (7% to 2.6-fold increase compared to normal weight). Patients aged 60–79 years, with a recent fracture or other drugs used for osteoporosis, had better persistence. Conclusions Over half of the patients initiating AOM stopped therapy within the first year after initiation. The described risk factors for cessation could be proxies for non-severe osteoporosis, and/or disease/risk awareness, which could inform the targeting of high-risk patients for monitoring and/or interventions aimed at improving persistence.

Más de la mitad de pacientes que inician tto anti-osteoporosis abandonan en 1 año. Datos AP España 2001-2013 #BIFAP
link.springer.com/article/10.1007%2Fs11657...

Trazodone utilization among the elderly in Spain. A population based study - PubMed Trazodone use is increasing in elderly patients, and a high proportion of use in non-approved indications was observed. Trazodone is not being used at high doses, but interacting medicines were frequent, and it may pose additional risks for elderly patients.

Trazodona en España: ↑uso en ancianos con ↑indicación off-label y ↑interacciones potenciales. Nuevo estudio #BIFAP http://ow.ly/DcOJ307WiXo

Oído en jornada #Bifap: Desde que colaboro con Bifap prescribo menos y mejor #MeaningfulUse #Como-se-empodera-un-Medico-Con-Datos-de-la-HCE

100% de acuerdo con Juan Erviti de @BITNavarra : #Bifap es una joya que debemos cuidar entre todos

Para saber más de #BIFAP http://bifap.aemps.es/

Osteoporosis: the emperor has no clothes - PubMed The evidence for the viability of bone-targeted pharmacotherapy in preventing hip fracture and other clinical fragility fractures is mainly limited to women aged 65-80 years with osteoporosis, whereas the proof of hip fracture-preventing efficacy in women over 80 years of age and in men at all ages …

Osteoporosis: the emperor has no clothes [J Intern Med] www.ncbi.nlm.nih.gov/pubmed/25809279
#Bifap: herramienta d valor para ayudar a buscar mejor sastre

Las tripas de #BIFAP: 5.902 descriptores semánticos cubren 94% de 67 millones diagnósticos y 2,6 millones descriptores diferentes de las HCE

En jornada #BIFAP: base de datos de gran valor orientada a investigación farnacoepidemiológica aemps.gob.es/eventosCongresos/2015/J-... #MeaningfulUse